Advertisement

Cell-Free DNA in Pediatric Rhabdomyosarcoma: Potential and Challenges

  • Lucia Tombolan
  • Angelica Zin
  • Gianni Bisogno
Protocol
Part of the Methods in Molecular Biology book series (MIMB, volume 1909)

Abstract

Rhabdomyosarcoma is an aggressive solid tumor that may disseminate hematogenously giving metastasis which represents the most important prognostic factor. Chances of an effective cure in childhood cancer rely on the capacity to make an early and accurate diagnosis, detect metastatic disease or relapse, and predict the response to treatment.

Liquid biopsy is a very promising blood test for cancer detection and noninvasive disease monitoring. This method has a great advantage to use blood and plasma, a more accessible biological material, quick and easy to obtain with minimal pain and risk for patients. In particular, circulating free DNA (cfDNA) represents a tumor biomarker detected in plasma that gives information on biology and genetic background of tumor.

Moreover, cfDNA mutation detection could be a reliable method to monitor the efficacy of treatment and to discover novel targets for a personalized treatment in pediatric solid tumor. Here, we describe an optimized protocol to cfDNA isolation from small amount of plasma, as well as a method to assess the quantity and quality of cfDNA. Finally, we propose ddPCR as a reliable method to detect mutations at low frequency in cfDNA obtained from pediatric rhabdomyosarcoma samples.

Key words

Cell-free DNA Rhabdomyosarcoma ddPCR Pediatric solid tumors Mutation detection 

Notes

Acknowledgments

The study was supported by AIRC Foundation (IG 15813 PI. Prof Bisogno), University of Padova (BIRD grant 2016–2018) and Fondazione Città della Speranza.

References

  1. 1.
    Parham DM, Barr FG (2013) Classification of rhabdomyosarcoma and its molecular basis. Adv Anat Pathol 20:387–397CrossRefGoogle Scholar
  2. 2.
    Huh WW, Skapek SX (2010) Childhood rhabdomyosarcoma: new insight on biology and treatment. Curr Oncol Rep 12:402–410CrossRefGoogle Scholar
  3. 3.
    Hawkins DS, Spunt SL, Skapek SX (2013) Children’s Oncology Group’s 2013 blueprint for research: soft tissue sarcomas. Pediatr Blood Cancer 60:1001–1008CrossRefGoogle Scholar
  4. 4.
    Schwarzenbach H, Hoon DSB, Pantel K (2011) Cell-free nucleic acids as biomarkers in cancer patients. Nat Rev Cancer 11:426–437CrossRefGoogle Scholar
  5. 5.
    Heitzer E, Ulz P, Geigl JB (2015) Circulating tumor DNA as a liquid biopsy for cancer. Clin Chem 61:112–123CrossRefGoogle Scholar
  6. 6.
    Alix-Panabieres C, Pantel K (2016) Clinical applications of circulating tumor cells and circulating tumor DNA as liquid biopsy. Cancer Discov 6:479–491CrossRefGoogle Scholar
  7. 7.
    Siravegna G, Bardelli A (2014) Genotyping cell-free tumor DNA in the blood to detect residual disease and drug resistance. Genome Biol 15:449CrossRefGoogle Scholar
  8. 8.
    Chicard M, Boyault S, Colmet Daage L et al (2016) Genomic copy number profiling using circulating free tumor DNA highlights heterogeneity in neuroblastoma. Clin Cancer Res 22:5564–5573CrossRefGoogle Scholar
  9. 9.
    El Messaoudi S, Rolet F, Mouliere F, Thierry AR (2013) Circulating cell free DNA: preanalytical considerations. Clin Chim Acta 424:222–230CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2019

Authors and Affiliations

  1. 1.Department of Woman’s and Children’s Health, Hematology and Oncology UnitUniversity of PadovaPadovaItaly
  2. 2.Institute of Pediatric Research (IRP), Fondazione Città della SperanzaPadovaItaly

Personalised recommendations